CLRB
Cellectar Biosciences INC NEWstockNASDAQ
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.16 | 2026-11-12 | -24.13% | 5.599 |
| 1M | 1.12 | 2026-10-19 | -21.42% | 1.869 |
| 3M | 2.62 | 2026-08-19 | -66.41% | 1.381 |
| 6M | 3.06 | 2026-05-19 | -71.24% | 1.523 |
| 1Y | 2.86 | 2025-11-19 | -69.23% | 1.636 |
| 2Y | 48.30 | 2024-11-19 | -98.18% | — |
| 5Y | 226.50 | 2021-11-19 | -99.61% | 1.175 |
Cellectar Biosciences INC NEW (NASDAQ:CLRB) stock price today is $0.88, and today's volume is 50,166. CLRB is down 4.368% today. The 30 day average volume is 143,281. CLRB market cap is $8.84M with 10.04M shares outstanding.
